BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8747401)

  • 1. Screening for ovarian cancer: what are the optimal surrogate endpoints for clinical trials?
    Karlan BY
    J Cell Biochem Suppl; 1995; 23():227-32. PubMed ID: 8747401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for ovarian cancer in the general population.
    Chu CS; Rubin SC
    Best Pract Res Clin Obstet Gynaecol; 2006 Apr; 20(2):307-20. PubMed ID: 16364690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Status of tumor markers in ovarian cancer screening.
    Bast RC
    J Clin Oncol; 2003 May; 21(10 Suppl):200s-205s. PubMed ID: 12743135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress and challenges in screening for early detection of ovarian cancer.
    Jacobs IJ; Menon U
    Mol Cell Proteomics; 2004 Apr; 3(4):355-66. PubMed ID: 14764655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional ultrasonography and power Doppler in ovarian cancer screening of asymptomatic peri- and postmenopausal women.
    Kurjak A; Prka M; Arenas JM; Sparac V; Merce LT; Corusic A; Ivancic-Kosuta M
    Croat Med J; 2005 Oct; 46(5):757-64. PubMed ID: 16158468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and early detection of ovarian cancer: mission impossible?
    Bast RC; Brewer M; Zou C; Hernandez MA; Daley M; Ozols R; Lu K; Lu Z; Badgwell D; Mills GB; Skates S; Zhang Z; Chan D; Lokshin A; Yu Y
    Recent Results Cancer Res; 2007; 174():91-100. PubMed ID: 17302189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.
    Fishman DA; Cohen L; Blank SV; Shulman L; Singh D; Bozorgi K; Tamura R; Timor-Tritsch I; Schwartz PE
    Am J Obstet Gynecol; 2005 Apr; 192(4):1214-21; discussion 1221-2. PubMed ID: 15846205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the early detection of ovarian carcinoma.
    Garner EI
    J Reprod Med; 2005 Jun; 50(6):447-53. PubMed ID: 16050569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.
    Mok SC; Chao J; Skates S; Wong K; Yiu GK; Muto MG; Berkowitz RS; Cramer DW
    J Natl Cancer Inst; 2001 Oct; 93(19):1458-64. PubMed ID: 11584061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian cancer screening. The role of ultrasound in early detection.
    Karlan BY; Platt LD
    Cancer; 1995 Nov; 76(10 Suppl):2011-5. PubMed ID: 8634993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on ovarian cancer screening.
    Munkarah A; Chatterjee M; Tainsky MA
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):22-6. PubMed ID: 17218847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early detection of ovarian cancer.
    Teneriello MG; Park RC
    CA Cancer J Clin; 1995; 45(2):71-87. PubMed ID: 7889392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection.
    Berek JS; Bast RC
    Cancer; 1995 Nov; 76(10 Suppl):2092-6. PubMed ID: 8635006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current status of ultrasound and color Doppler imaging in screening for ovarian cancer.
    Karlan BY; Platt LD
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S28-33. PubMed ID: 7835806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.
    Skates SJ; Horick N; Yu Y; Xu FJ; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Woolas RP; Jacobs IJ; Zhang Z; Bast RC
    J Clin Oncol; 2004 Oct; 22(20):4059-66. PubMed ID: 15381683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New tumor markers: CA125 and beyond.
    Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
    Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian cancer screening-ultrasound; impact on ovarian cancer mortality.
    Kamal R; Hamed S; Mansour S; Mounir Y; Abdel Sallam S
    Br J Radiol; 2018 Oct; 91(1090):20170571. PubMed ID: 30102555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare.
    Bast RC
    Trans Am Clin Climatol Assoc; 2004; 115():233-47; discussion 247-8. PubMed ID: 17060970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
    Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.